Stockreport

Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]

Eupraxia Pharmaceuticals Inc.  (EPRX) 
PDF At lower doses, patients maintained the improvements in tissue health reported at week 12 out until week 36. Clinical remission was achieved by 8 weeks and maintained [Read more]